Le Lézard
Classified in: Covid-19 virus

Amdocs Solution Deployed to Deliver Seamless User Experience on Hubbl, Australia's Newest Streaming Aggregation Product


Amdocs Subscription Marketplace simplifies the subscription experience for customers and enables easy onboarding and integration of partner services on Hubbl

JERSEY CITY, NJ / ACCESSWIRE / May 8, 2024 / Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, announced today that Foxtel Group, a leading Australian subscription TV and streaming provider, has successfully deployed Amdocs Subscription Marketplace onto Australia's newest streaming aggregation product, Hubbl, that fuses live TV and streaming into one simple viewing experience.

Through Amdocs Subscription Marketplace, global streaming content apps are integrated on the Hubbl platform, alongside local broadcast video on-demand apps, driving a seamless user experience as well as operational efficiencies through simplified and accelerated partner onboarding.

"Hubbl is the future of technology and streaming, fusing free and paid entertainment and sports content from apps, channels, live TV, and the internet into a single platform," said Les Wigan, Managing Director of Hubbl. "The successful and speedy deployment of Amdocs Subscription Marketplace helped us integrate all the streaming apps onto one platform, enhancing the user experience for our customers."

"Today's customers seek seamless, integrated digital experiences with the tap of a finger or click of a button," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "We are thrilled to expand our collaboration with Foxtel as they adopt our Subscription Marketplace, bringing some of the most popular global content applications onto their new streaming platform. This engagement positions Foxtel to drive subscriber growth and provide end users with a frictionless service experience, ultimately leading to increased customer lifetime value (CLTV)."

Supporting Resources

About Amdocs
Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and enterprise customers. Our approximately 29,000 employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $4.89 billion in fiscal 2023. For more information, visit www.amdocs.com

Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macro-economic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other global or regional events such as the recent attacks in Israel and evolving conflict and the COVID-19 pandemic, as well as the current inflationary environment, and the effects of these conditions on the company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the company's offerings and operations and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2023 filed on December 13, 2023 and our Form 6-K furnished for the first quarter of fiscal 2024 on February 20, 2024.

Media Contacts
Swati Sharma
Amdocs Public Relations
E-mail: [email protected]

SOURCE: Amdocs Management Limited



View the original press release on accesswire.com


These press releases may also interest you

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 17:15
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...

18 mai 2024
Emmy-winning actor and St. Louis native Jon Hamm took the stage Saturday, May 18, to offer words of wisdom to the newest graduates of Saint Louis University (SLU) during the University's spring commencement in St. Louis. ...

18 mai 2024
Nearly 900 undergraduates of the Class of 2024 celebrated their send-off from Bentley University in a very different way than their 2020 arrival amid the COVID-19 pandemic. The 105th undergraduate commencement ceremony was marked by maskless smiles,...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: